%0 Journal Article
%T PARP抑制剂在卵巢癌维持治疗中的研究进展<br>Research Progress of PARP Inhibitors in Maintenance Therapy of Ovarian Cancer
%A 陈建兵
%A 刘茹艳
%A 翟静宇
%A 王国庆
%J Advances in Clinical Medicine
%P 562-572
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.153649
%X 卵巢癌是妇科疾病中预后最差的恶性肿瘤&#65292;由于早期症状不典型、缺乏特异性&#65292;所以早期诊断困难。初始治疗后复发率高&#65292;5年总生存率仅为40%&#65292;晚期卵巢癌的治疗成为临床工作中的难题。近年来&#65292;PARP抑制剂的应用&#65292;极大地改善了卵巢癌患者的生存期时间。PARP抑制剂作为一种新型的靶向治疗药物&#65292;在卵巢癌的维持治疗中取得了显著进展。本文对PARP抑制剂在卵巢癌维持治疗中的作用机制、临床研究、安全性等方面的研究进展进行综述&#65292;旨在为卵巢癌的临床治疗提供参考。<br>Ovarian cancer is a malignant tumor with the worst prognosis in gynecological diseases, and early diagnosis is difficult because of the untypical early symptoms and lack of specificity. The recurrence rate after initial treatment is high, the 5-year overall survival rate is only 40%, and the treatment of advanced ovarian cancer has become a difficult problem in clinical work. In recent years, the application of PARP inhibitors has greatly improved the survival time of ovarian cancer patients. As a new type of targeted therapy, PARP inhibitors have made remarkable progress in the maintenance therapy of ovarian cancer. In this paper, the research progress of the mechanism of action, clinical research and safety of PARP inhibitors in the maintenance treatment of ovarian cancer is reviewed, aiming to provide a reference for the clinical treatment of ovarian cancer.
%K 卵巢癌&#65292
%K PARP抑制剂&#65292
%K 维持治疗&#65292
%K 综述<br>Ovarian Cancer
%K PARP Inhibitors
%K Maintenance Therapy
%K Review
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=108950